• Users Online: 830
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
RESEARCH ARTICLE
Year : 2020  |  Volume : 5  |  Issue : 1  |  Page : 5-17

Hotspots and prospects of stem cell therapy for type 2 diabetes: bibliometric and visual analysis based on publications, clinical registries, drug approval information, and patent information in China and the United States


Editorial Office of Chinese Journal of Tissue Engineering Research, Shenyang, Liaoning Province, China

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2542-3975.281716

Rights and Permissions

Background and objective: Healthy diet, exercise, drugs, and insulin-based interventions can help control the progression of type 2 diabetes. However, these methods are insufficient for advanced disease progression. Previous studies found that the transplantation of stem cells to repair or replace damaged tissues and cells is a promising treatment for type 2 diabetes. This article aimed to summarize and visualize the current status and frontiers of research into stem cell therapies for type 2 diabetes, both in China and globally. Methods: WanFang (China) and Web of Science (United States) entries were retrieved for studies on stem cell therapies for type 2 diabetes. Visualization techniques were used to analyze publication year, country, institutional affiliation, author, journal, funding source, and keywords, as well as to compare the distribution of different types of stem cells for the treatment of type 2 diabetes. We also retrieved relevant clinical trial, drug, and patent information available from the Chinese Clinical Trial Registry, ClinicalTrials.gov, China National Medical Products Administration, US Food and Drug Administration, China National Intellectual Property Administration, and US Patent and Trademark Office. Results and conclusion: We found that: (1) stem cell therapy for type 2 diabetes was first reported in 1998. Thereafter, the number of relevant studies has risen at a slow rate, but increased rapidly since 2012. In China, stem cell therapy for type 2 diabetes was first reported in 2000, two years later than the first publication globally. (2) Bone marrow mesenchymal stem cells and pancreatic stem cells are the main types of stem cells used in China for treatment of type 2 diabetes. (3) In China, studies regarding stem cell therapy for type 2 diabetes were mainly associated with Shanghai Jiao Tong University, Peking Union Medical College, Chinese Academy of Medical Sciences, and Affiliated Hospital of Qingdao University School of Medicine. In the United States, relevant articles were mainly from the University of California and Harvard University. (4) In China, stem cell therapy for type 2 diabetes was mainly reported in two core journals, Chinese Journal of Tissue Engineering Research and Chinese Journal of Diabetes Mellitus, whereas, PLoS One, Diabetes, Diabetologia, and Stem Cell Research Therapy were the major relevant journals worldwide. (5) Globally, institutions providing major sources of funding for stem cell therapy for type 2 diabetes included the US National Institutes of Health, US Department of Health and Human Services, and National Natural Science Foundation of China. (6) There were four relevant clinical registries in the China Clinical Trial Registry and 17 on ClinicalTrials.gov. (7) No approval of stem cells as a treatment for type 2 diabetes has been issued in China or other countries. However, numerous relevant patents have been filed. Here, we report development trends, research hotspots, and the distribution features of stem cells for the treatment of type 2 diabetes. Our results provide relevant experimental data in chronological order for further use in clinical practice.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4817    
    Printed359    
    Emailed0    
    PDF Downloaded350    
    Comments [Add]    

Recommend this journal